Financial Profile
  
   
UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE, 2002
  
Rs in million
--
Quater Ended
Year Ended
30.06.2002
30.06.2001
31.03.2002
(Audited)
1
Net Sales & Income from Operations
4029.5
2991.8
14005.1
2
Other Income
47.8
48.3
283.6
3
Total Expenditure
-
-
-
    
a) (Increase) / decrease in Stock-in -trade
(212.8)
(147.5)
(850.9)
   
b) Consumption of  Materials
1978.8
1537.7
6907.5
c) Staff Cost
196.8
154.2
632.5
d) Other Expenditure
1244.0
861.7
4272.1
4
Interest
2.3
2.5
21.0
5
Depreciation
70.0
47.5
212.8
6
Profit (+) / Loss (-) before Tax     (1+2-3-4-5)
798.2
584.0
3093.7
7
Provision for Taxation
191.9
140.0
1017.4
8
Net Profit (+) / Loss (-) (6-7)
606.3
444.0
2076.3
9
Paid-up Equity Share Capital
599.7
599.7
599.7
10
Reserves excluding Revaluation Reserves
(as per balance-sheet of previous accounting year)
-
-
8616.8
11
Earning per Share
* Not Annualised
*10.11
*7.40
34.62
Notes:
1
Provision for tax includes deferred taxation
2
The Company is exclusively in the pharmaceutical business segment
3
The Directors at their meeting held today recommended payment of dividend of Rs.7 per equity share of Rs.10/- each for the year 2001 - 2002 amounting to Rs.419.81 million.
4
The figures of the previous year have been regrouped to render them comparable with the figures of the current year.
5
The above results were taken on record at the meeting of the Board of Directors held on 24th July, 2002.
By order of the Board
For CIPLA LIMITED
   
Mumbai
24th July, 2002.

 
M. K. Hamied
Joint Managing Director